When was Celsius Therapeutics founded?

Celsius Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Celsius Therapeutics located?

Celsius Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Celsius Therapeutics have?

As of Mar 01, 2026, the latest employee count at Celsius Therapeutics is 10 - 49.

Is Celsius Therapeutics a funded company?

Celsius Therapeutics is a funded company, having raised a total of $148M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 03, 2019.

When was the latest funding round of Celsius Therapeutics?

Celsius Therapeutics' latest funding was a $***** Series B round on Mar 24, 2022, with participation from 11 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.36B in funding in 2026 to date.

Where does Celsius Therapeutics rank among its competitors?

Celsius Therapeutics ranks 56th amongst 357 active competitors, of which 122 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was GenSight Biologics, which secured $1.96M in Mar, 2026.

Who are the top competitors of Celsius Therapeutics?

Celsius Therapeutics' top competitors include MedGenome, Geneoscopy and Intellia Therapeutics. Among them, GenSight Biologics secured the most recent funding round in March, 2026.

Celsius Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Q: Is Celsius Therapeutics an acquired company?

Celsius Therapeutics got acquired by AbbVie on Jun 27, 2024.

Company Details

Provider of single-cell RNA and genomic analysis. The company focuses on precision therapeutics for autoimmune diseases and cancer. The company combines single-cell genomic sequencing with computational algorithms to discover precision therapies.

Website: celsiustx.com
Social
Email ID: *****@celsiustx.com
Phone Number: +1 **********
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2018

Location

Cambridge, United States

Stage

Acquired

Total Funding

$148M in 2 rounds

Latest Funding Round

Series B, Mar 24, 2022, $*****

Investors

Third Rock Ventures & 12 more

Ranked

56^th among 357 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

MedGenome & 504 more

Exit Details

Acquired by AbbVie (Jun 27, 2024)

View Celsius Therapeutics' full profile

Celsius Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CELSIUS THERAPEUTICS, INC. CIN: 821231573 , United States, Active	Dec 26, 999	-	4 (As on Dec 31, 2023)	-

Celsius Therapeutics got acquired by AbbVie on Jun 27, 2024 at an acquisition amount of $*****.

Click here to take a look at Celsius Therapeutics's acquisition in detail

Celsius Therapeutics has raised a total funding of $148M over 2 rounds. Its first funding round was on Oct 03, 2019. Its latest funding round was a Series B round on Mar 24, 2022 for $*****. 11 investors participated in its latest round. Celsius Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Celsius Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 24, 2022	8931495	Series B	9271891	8845128	2782975	2769219
Oct 03, 2019	1381203	Series A	3543176	6560921	Third Rock Ventures	Google Ventures & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Celsius Therapeutics's funding rounds and investors

The founders of Celsius Therapeutics are Jeffrey Bluestone, Ramnik Xavier, Aviv Regev and Vijay Kuchroo.

Here are the details of Celsius Therapeutics' key team members:

Jeffrey Bluestone: Co-Founder of Celsius Therapeutics and founder of 1 other company.
Contact Info: 1 email address
Ramnik Xavier: physician scientist of Celsius Therapeutics.
Aviv Regev: Co-Founder of Celsius Therapeutics.
Vijay Kuchroo: Co-Founder of Celsius Therapeutics.

View details of Celsius Therapeutics's Founder profiles and Board Members

Celsius Therapeutics' employee count trend

Celsius Therapeutics has 10 - 49 employees as of Mar 26. Here is Celsius Therapeutics's employee count trend over the years:

Employee count trend for Celsius Therapeutics

Uncover Celsius Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Celsius Therapeutics include MedGenome, Geneoscopy and Intellia Therapeutics. Here is the list of Top 10 competitors of Celsius Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	71/100
2nd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
3rd	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Orbimed & 10 others	66/100
4th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	66/100
5th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Foresite Capital & 11 others	62/100
6th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
7th	Exicure 2009, Skokie (United States), Public	developer of gene silencing & immunomodulatory drugs using spherical nucleic acid (SNA) technology	$72.3M	Abbott Biotech Ventures, Luye Pharma & 18 others	61/100
8th	GenSight Biologics 2011, Paris (France), Public	Developer of viral vector-based gene therapies for retinal neurodegenerative diseases	$76.6M	Jennison, Perceptive Advisors & 17 others	61/100
9th	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
10th	Repare Therapeutics 2016, Montreal (Canada), Acquired	Developer of targeted therapies to address the genetic alterations associated with selected tumors	$166M	Cowen, Bristol-Myers Squibb & 13 others	60/100
56th	Celsius Therapeutics 2018, Cambridge (United States), Acquired	Provider of single-cell RNA and genomic analysis	$148M	Acks, Google Ventures & 11 others	49/100